## LRCX: Lam Research Corporation - XLK: Technology

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 5.7% in lower entry zone (4.0-10.0%), top 4% cross-sectional ranking. Caution: MRS_5 (-0.0%) diverging from MRS_20, watch for reversal. Outperforming sector by 5.4%. Caution: declining volume (45% of avg), momentum weakening (-2.5% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($163.51)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Lam Research near $180 as year-end positioning puts chip-tool stocks back in play**
- Source: ts2.tech | 20251229T040825 | Somewhat-Bullish | Relevance: 100%
- Lam Research shares closed up 0.4% at $178.07 on Friday, with many watching for year-end positioning and upcoming Fed minutes. The company's fiscal quarter ended on December 28th, and investors are anticipating its December-quarter results, which will be measured against prior guidance. A Zacks analyst report highlighted Lam Research's strong position in 3D DRAM and advanced packaging, key areas for chipmaking complexity.

**2. Lam Research Stock (LRCX) Holds Near Record Highs Into Year-End: Latest Headlines, Analyst Targets, and What to Watch Before Mondayâ€™s Open**
- Source: ts2.tech | 20251228T170833 | Somewhat-Bullish | Relevance: 100%
- Lam Research (NASDAQ: LRCX) closed at an all-time high of $178.07 on Friday, December 27, 2025, riding the "AI infrastructure" trade momentum. The article details recent institutional investor activity, analyst targets ranging from bullish to moderate, and an executive's recent insider stock sale (executed under a 10b5-1 plan). Investors are advised to monitor year-end positioning, the broader semiconductor market, and upcoming earnings season for further cues.

**3. B. Riley Names Lam Research (LRCX) a Top Memory Recovery Play Due to Specialized Etch Leadership**
- Source: Finviz | 20251228T124600 | Bullish | Relevance: 100%
- B. Riley has named Lam Research (LRCX) a top memory recovery play, raising its price target to $195 due to the company's specialized etch leadership. Mizuho and Bank of America also raised their price targets, citing optimism for 2026 WFE estimates and an upgrade cycle for AI-driven workloads. Lam Research designs and manufactures semiconductor processing equipment globally, with analysts viewing its leadership in complex memory architectures as a significant growth driver.

**4. B. Riley Names Lam Research (LRCX) a Top Memory Recovery Play Due to Specialized Etch Leadership**
- Source: Insider Monkey | 20251228T124600 | Bullish | Relevance: 100%
- B. Riley has named Lam Research (LRCX) a top memory recovery play, raising its price target to $195 from $180 due to the company's specialized etch leadership. Other analysts, including Mizuho and Bank of America, also increased their price targets for Lam Research, citing optimism regarding WFE estimates and AI-driven infrastructure upgrades. Lam Research designs and manufactures semiconductor processing equipment and is recognized as one of the best-performing S&P 500 stocks in 2025.

**5. Encompass More Asset Management Purchases Shares of 9,753 Lam Research Corporation $LRCX**
- Source: MarketBeat | 20251229T094430 | Somewhat-Bullish | Relevance: 100%
- Encompass More Asset Management recently acquired 9,753 shares of Lam Research Corporation (NASDAQ: LRCX) during Q3, totaling approximately $1.306 million. Other institutional investors also adjusted their holdings in the semiconductor company. Lam Research reported strong Q3 earnings, surpassing analyst estimates, but significant insider selling has occurred, with institutional ownership standing at 84.61%.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-23 | UBS | $200 | $175 | +14% |
| 2025-12-18 | B. Riley Securi | $195 | $180 | +8% |
| 2025-12-17 | Mizuho | $200 | $170 | +18% |
| 2025-12-15 | Jefferies | $200 | $175 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-23 | UBS | main | Buy |
| 2025-12-18 | B. Riley Securi | main | Buy |
| 2025-12-17 | Mizuho | main | Outperform |
| 2025-12-15 | Jefferies | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 12 ($2.00M) |
| Sells | 6 ($14.54M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.4% (+0.3%)
- Blackrock Inc.: 9.9% (+1.7%)
- JPMORGAN CHASE & CO: 4.8% (+47.4%)
- State Street Corpora: 4.8% (+0.4%)
- Geode Capital Manage: 2.7% (-0.5%)

### Key Risks

1. Heavy insider selling: $15M sold (6 transactions in 90 days).
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 5 raises (avg +14%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.20 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 62%, ROA 20%, margin 30%). Balance sheet: strong liquidity (2.2x), $1.6B free cash flow. Analyst sentiment positive (5 raises, avg +14%). Insider selling cluster ($14.5M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $221.8B |
| Beta | 1.78 |
| 52W Range | $56.32 - $179.80 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.20 |
| Forward P/E | 31.2 |
| Current P/E | 36.3 |
| YoY Growth | 16.3% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 8.2% to 5.7% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 96th percentile. MRS_5 (-0.0%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 6.1% shows strong absolute momentum above own 20MA. Outperforming sector by 5.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.11), confirming momentum. Volume at 45% of 20MA suggests lack of conviction. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.69% (CS: 96) | Strong |
| RSI_14 | 62.5 | Neutral |
| MACD Histogram | 1.11 | Bullish |
| vs SMA20 | 1.061x | Above |
| vs SMA50 | 1.112x | Above |
| vs SMA200 | 1.583x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $175.87
- **Stop Loss:** $163.51 (7.0% risk)
- **Target:** $194.41 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 93
- **Position Value:** $16,355.91
- **Portfolio %:** 16.36%
- **Risk Dollars:** $1,150.00
- **Risk Per Trade:** 1.15%
- **Modifiers:** L1 115% | L2 100% | Combined 1.15x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-01-28 (Est: $1.16)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.22 | $1.26 | +3.3% |
| 2025Q2 | $1.21 | $1.33 | +10.4% |
| 2025Q1 | $1.00 | $1.04 | +4.1% |
| 2024Q4 | $0.88 | $0.91 | +3.5% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*